CompletedPHASE2, PHASE3NCT00070187
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Studying Post-transplant lymphoproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Allen R. Chen, MD, PhD, MHSSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Intervention
- aldesleukin(biological)
- Enrollment
- 24 target
- Eligibility
- 30 years · All sexes
- Timeline
- 2003
Study locations (30)
- Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
- Children's Hospital and Research Center - Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States
- Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida Shands Cancer Center, Gainesville, Florida, United States
- Nemours Children's Clinic, Jacksonville, Florida, United States
- University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Miami Children's Hospital, Miami, Florida, United States
- All Children's Hospital, St. Petersburg, Florida, United States
- St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00070187 on ClinicalTrials.govOther trials for Post-transplant lymphoproliferative disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06723457Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern University
- RECRUITINGPHASE1, PHASE2NCT07368634Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06954805Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Jennifer Amengual
- RECRUITINGPHASE1, PHASE2NCT07438067EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell TransplantationDaihong Liu
- ACTIVE NOT RECRUITINGNCT06422715PTLD: Multicentric Retrospective StudyFondazione Italiana Linfomi - ETS
- RECRUITINGPHASE1, PHASE2NCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Washington University School of Medicine
- RECRUITINGPHASE2NCT05453396Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesUniversity of Washington
- RECRUITINGPHASE2NCT05786040Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderTimothy Voorhees
See all trials for Post-transplant lymphoproliferative disease →